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Opinion statement
Allergen immunotherapy (AIT) is an immune modulating treatment for allergic diseases.
Although highly effective, some patients do not respond to the treatment. To date there
are no surrogate biomarkers that are predictive of the clinical response to AIT. More and more
is known about the underlying immunological mechanism involved in AIT. Through modula-
tion of both innate and adaptive immune responses, involving reduced ILC2 and enhanced
Treg and Breg induction and functionality, along with induction of IgG4 antibody production
which have the capacity to inhibit both allergen-induced basophil responsiveness and CD23-
mediated IgE-facilitated allergen presentation, the result is an immune skewing towards a
more balanced Type I response. So far, however there is not a clear correlation with the
observed immunological changes and predictive correlates of clinical efficacy. The most
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promising biomarker of successful AIT is IgE-FAB as a reflection of functional IgG4. Cellular
responses and cytokine analysis gives a great deal of insight into the mechanisms of AIT but
may not represent useful or indeed reliable biomarkers in a clinical setting. There is a need for
more research for confirmation and interpretation of the possible association with biomarkers
and clinical response to AIT.
Introduction
Allergen immunotherapy (AIT) is the only disease-mod-
ifying therapy available for IgE-mediated diseases such as
allergic rhinitis, allergic asthma and atopic dermatitis[1,
2]. AIT is a safe and effective treatment indicated only in
those patients whose symptoms are mostly uncontrolled
by conventional pharmacotherapy such as antihista-
mines or nasal steroids [3, 4]. AIT, which can be admin-
istered either subcutaneously (SCIT) or sublingually
(SLIT), reduces both symptoms and the need of rescue
medication [5–7], improves patient’s quality of life [8]
and confers long-term clinical benefits after cessation of
treatment [9, 10••, 11, 12, 13•]. Although AIT is effective,
the degree of remission depends on several unidentified
factors (1, 6, 13•, 14–17). It is therefore, essential to
determine biomarkers that would: identify those patients
most likely to respond to therapy; indicate when to stop
treatment; predict symptomatic relapse and inform on
when to perform a booster AIT. Application of such
knowledge, would undoubtedly contribute to the use of
biomarkers of AIT in personalised medicine [18]. Novel
insight in to themechanismwhich govern AIT is essential
for the identification of robust biomarkers. This review
presents an updated overview of the underlying mecha-
nism and novel potential biomarkers of AIT.
Mechanisms of AIT
The allergic response cascade is characterized by a complex network of dysregulat-
ed immunological events. Through the administration of high allergen dose
during AIT, both innate and adaptive immune responses are modulated. Efficacy
of, and tolerance induction through AIT has been shown to be associated with
decreased numbers of infiltrating mast cells [19, 20•], basophils [21], and eosin-
ophils in the nasalmucosa [20•, 22], in addition to a reduction in the frequency of
group 2 innate lymphoid cells (ILC2) [23••] and type 2 T helper (Th2) cells [24,
25•], in the periphery. AIT modulates dendritic cell responses (DCs) [26] which
leads to immune deviation from T helper type 2 to type 1 response, induction of
interleukin (IL)-10+, IL-35+, TGF-β+ and generation of FoxP3+ regulatory T cells.
Moreover, IL-10+ B regulatory cells and IgG4 antibodies responses during and after
cessation of AIT have been observed [27–31]. These antibodies have the capacity to
inhibit both allergen-induced basophil responsiveness and CD23-mediated IgE-
facilitated allergen presentation [10••]. Understanding the mechanisms of AIT is
essential as it paves the way to identify novel determinant biomarkers of AIT
success and therapeutic targets which when combined with AIT could potentially
restore an immune tolerance state.
Immunomodulation of ILC2s and IL13+ ILC2s by AIT
Innate lymphoid cells (ILCs) are morphologically similar to lymphocytes but
lack the rearranging antigen receptors [32]. ILCs can be grouped into three
known subsets: ILC1, ILC2, and ILC3 (Fig. 1), which is defined by a
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combination of surface markers, transcription factors that are critical for their
generation, and cytokines that they produce [33].
In particular, ILC2 effector function is driven by epithelial derivedmediators IL-
33 [34], IL-25 [35], TSLP [36], as well as leukotriene D4 to produce Th2 cytokines
such as IL-4, IL-5, IL-9, and IL-13 [33]. ILC2s promote type 2 allergic inflammation,
and tissue repair [33]. First described in mouse, an analogous population of ILC2
was identified in human skin, revealing a population of Lin− CD25+ ST2+ c-Kit+
CD127+ ICOS+ which did not express markers of ILC3, CD4, NKp46, and ROR t
[36]. Shortly after, the presence of ILC2s, which shared the same morphology as
those in the skin, was confirmed in other organs [37]. Skin-specific expression of IL-
33 in transgenic mice was associated with atopic dermatitis like cutaneous appear-
ance. These mice had increased levels of Lin−ST2+ Sca-1+ ILC2s in the skin lesions,
peripheral blood, and regional lymph nodes. Lin−ST2+ Sca-1+ produced IL-5 and
IL-13 in response to IL-33 compared to wild-type mice that did not produce this
effect in the lymph nodes, suggesting that IL-33 stimulates ILC2s [34]. However,
Kim andColleagues [36] reported that the ILC2s were induced by TSLP in an IL-33
independent manner. It was further elucidated that the response of ILC2s to TSLP,
IL-25, or IL-33 regulated skin inflammation. High levels of ILC2swere found in the
skin of atopic dermatitis with the elevated expression of IL-17RB (IL-25R), ST2
Fig. 1. Innate lymphoid cells. Three groups of non-cytotoxic lineage negative ILCs are defined as ILC1, ILC2, and ILC3. ILCs express
the subunits of cytokine receptors such as interleukin (IL)-2 receptor-α (CD25) and IL-7 receptor-α (CD127) but do not express the
somatically rearranged antigen receptors as T and B cells and lack antigen specificity. Thus exhibit functions in an antigen-
independent manner. ILC1s produce IFN-γ in response to IL-12 and IL-18 providing immunity to intracellular bacteria and parasites.
Whereas ILC2s are stimulated by IL-25, IL-33, or TSLP to produce Th2 cytokines such as IL-5, IL-13, and IL-9 causing allergic
inflammation. ILC2s also provide immunity to helminths as well as tissue repair. The ILC3s are driven by IL-23, IL-1β to produce IL-
17, IL-22, and IFN-γ, which promote immunity to extracellular bacteria and tissue repair.
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(IL-33R), and TSLP receptors. The increased expression was associated with elevat-
ed levels of IL-25 and IL-33 expression. BALB/c strain mice deficient in cytokine
receptors for IL-33, IL-25, and TSLP had decreased skin inflammation of ear tissue
and skin-draining lymphnodes; however in response to TSLP, the reduction in skin
inflammation was moderate. These findings confirmed these cytokines are in-
volved in the regulation of ILC2s in the pathogenesis of atopic dermatitis, an IgE-
mediated disease [37].
The relevance of ILC2s to the pathophysiology of allergic rhinitis was firstly
demonstrated in subjectswhounderwent intranasal cat allergen provocation [38•].
Nasal cat allergen challenge resulted in an increase of peripheral blood ILC2s
expressing CD84. Diluent challenge resulted in no change in the percentage of
ILC2swhereas the levels of ILC2swere promptly elevated after 4 hwhen challenged
with cat allergen. These findings indicated that acute induction of ILC2s could play
a role in the pathogenesis of allergic rhinitis [38•]. Moreover, peripheral blood
CD117+ILC2s and IL-13+ILC2s have been shown to be increased in grass pollen
allergic individuals with seasonal allergic rhinitis following natural grass pollen
allergen exposure during the pollen season compared to out of the pollen season
[23••]. Grass pollen SCIT blunted the seasonal increases ofCD117+ILC2s aswell as
IL-13+ILC2s [23••]. Interestingly, the proportion of ILC2 correlated with visual
analog scores in allergic and treated individuals during the pollen season [23••]. It
is important to note that outside the pollen season, the frequency of CD117+ILC2s
and IL-13+ILC2s between grass pollen allergics and non-allergic controls remained
unaltered [23••]. These findings were confirmed by recent reports that demon-
strated that the number of ILC2s found in the peripheral blood of allergic subjects
were similar to the non-allergics [39]. However, allergic asthmatics had elevated
numbers of ILC2s and ILC3s in the periphery. This study also confirmed that the
frequency of ILC2s and ILC3s were high during the grass pollen season in those
that were sensitized to grass pollen allergen. In addition, a short 4-month SLIT did
not reduce the frequency of ILC2s. It is likely that the discrepancy of findings
between the SCIT and SLIT study was due to the enumeration of ILC2s in active
and placebo groups being conducted outside of the pollen season [39]. More
studies are needed to evaluate the effect of AIT on ILC2s and whether there is a
relationship between ILC2s and clinical response to AIT.
Molecular markers of DCs as biomarkers AIT success
Dendritic cells are the key orchestrators of both the innate and the adap-
tive immune responses, one aspect of which includes regulation of T cell
responses. When triggered by an allergen, immature DCs polarize into
DC1s, DC2s, DC17s, or DCregs, which in turn can differentiate T cells
into Th1 cells (DC1s), Th2 cells (DC2s), Th17 cells (DC17s), or regulatory
T cells (DCregs) [40••]. Gueguen and colleagues showed that DCregs or
tolerogenic DCs were generated when DCs were exposed to dexametha-
sone (DEX), which resulted in an increased expression of Ig-like transcript
2 (ILT2) and Ig-like transcript 4 (ILT4). Co-culture of tolerogenic DCs with
CD4+ T cells resulted in upregulation of IL-10 but not Foxp3. Moreover,
DC1 and DC17 effector DC markers such as CD71, FSCN1, IRF4, NMES1,
MX1, and TRAF1 were significantly upregulated. Interestingly, tolerogenic
DC markers were associated with ANXA1, complement component 1
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(C1Q), CATC, GILZ, F13A, FKBP5, Stabilin-1 (STAB1), and TPP1 mole-
cules. ANXA1 and FKBP5 were overexpressed in regulatory DCs. The ex-
pression of C1Q A, B, and C, as well as STAB1 was increased in peripheral
blood of monocyte derived tolerogenic DCs in subjects of who received
sublingual grass pollen immunotherapy. C1QA, C1QB, C1QC, and STAB1
were also found to be upregulated in patients with confirmed clinical
response to treatment. The C1Q and STAB1 expression was consistently
induced in response to treatment and also correlated with clinical benefit
in SLIT-treated patients [41]. Gueguen and colleagues identified additional
molecular markers that are differentially regulated in DC2s and DCregs,
evaluated their role as predictive biomarkers of efficacy. Changes in ex-
pression of 5 combined DCreg/DC2-associated markers in PBMCS corre-
lated with clinical efficacy of SLIT at 2 and 4 months. Interestingly, the
four markers of DC2 cells (CD141, GATA3, OX40L, and RIPK4) were
decreased after 4 months of AIT in allergic rhinitis patients, whereas the
expression of 4 DCreg cell markers (i.e., C1QA, FcεRIIIA, FTL, and
SLCO2B1) were increased in the peripheral blood of allergic rhinitics. This
implies that AIT stimulates the expression of markers for DC2 and DCreg
cells associated with clinical efficacy [40••]. After 2 and 4 months of AIT,
the optimal combination of five molecular markers of which three DC2
(CD141, GATA3, and RIPK4) and two DCreg (C1QA and FcγRIIIA) result-
ed in effective classification of clinical responders from non-responders.
The combined markers had a sensitivity of 90.48% and a specificity of
61.9%. Although, these findings were very interesting, they need to be
validated in large clinical studies of SCIT, SLIT and then in clinical practice.
T cell responses and AIT
Inflammatory responses in allergic diseases are widely considered to be
Th2 mediated. Th2 cytokines such as IL-4, IL-5, and IL-13 subsequently are
responsible for the induction of effector cells [42]. The production of
specific IgE by B cells is also facilitated by Th2. AIT is associated with
immune deviation from Th2 to Th1 responses and induction of regulatory
T cells. Regulatory T cells (Tregs) modulate the immune response, mediate
immune tolerance, and prevent autoimmune diseases [43]. A substantial
body of evidence also suggests that Tregs play an important role in the
control of allergy. AIT can drive the immune response towards induction
of Treg cells resulting increased IL-10 and TGF-ß production and suppres-
sion of IgE production [30]. During AIT, the number of Th2 memory cells
is reduced with an induced Treg/Th1 response [44]. Treg cells can be
induced through high-dose allergen exposure, such as multiple stings
received by beekeepers and prolonged, domestic cat-allergen exposure
which have been demonstrated to induce IL-10-mediated tolerance and
increased levels of antigen-specific IgG4. Furthermore, T cells producing IL-
10 as well as Foxp3+IL-10+ T cells were shown to be increased in nasal
mucosa of immunotherapy patients one [45]. IL-10 has an important role
in the control of allergy by suppressing allergic inflammation and inducing
regulatory T cells. The balance between allergen-specific T cell subsets may
be influenced by AIT, as Tr1 cells have been found to be reduced in
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peripheral blood for atopic patients but increased in AIT treated patients
[25•]. To summarize, Tregs appear to play an essential role in the induc-
tion of tolerance in AIT suppressing the allergic Th2 response and inducing
the more tolerant Th1 state. Identifying their true relationship to clinical
response remains to be investigated.
B regulatory cells and immune tolerance
Regulatory B cells (Bregs) are a subset of CD19+B cells that produce IL-10 andhave
the capacity to supress pro-inflammatory T and B cell effector function. Bregs
promote immune tolerance state through production of interleukin-10 (IL-10),
IL-35 and transforming growth factor b (TGF-β). IL-10-producing B cells have been
most extensively studied for their regulatory potential inman andmice. To date, IL-
10+ B cells have been reported to reside within CD1dhiCD5+, CD24hiCD27+,
CD25+CD71+CD73- and CD24hiCD38hi B cell subsets [46••]. IL-10 producing
CD25+CD71+CD73- Breg subset has been shown to be induced following AIT.
They regulate pro-allergic immune responses by inhibiting antigen-specific CD4+ T
cell proliferation and produce anti-inflammatory IgG4 antibodies [46••]. Breg cells
control excessive inflammatory responses through IL-10 secretion, and are involved
in Treg cells differentiation by inhibiting release of proinflammatory cytokines
[47•]. In bee-venom, tolerant individual, highly purified IL-10-secreting Breg cells
were phenotypically characterized via high expression of surface CD25 and CD71
level but low level of CD73 (Human BR1 cells, CD73-CD25+CD71+ B cells)
[46••]. In vitro studies revealed their capacity to suppress antigen-driven PBMCs
proliferation. In the same study, bee-venom allergen (PLA2)-specific CD19+ B cells
were increased following bee-venom AIT and produced IL-10 [46••].
Functional IgG4 antibodies as potential biomarkers of AIT
An immunologic response following administration of large doses of the
sensitizing allergen either by SCIT or SLIT has been associated with the induc-
tion of serum allergen-specific immune reactive and functional IgG antibodies
(sIgG). A 10–100fold increase in the concentrations of allergen-specific IgG1
and, in particularly of IgG4 antibodies has been reported in several SCIT and
SLIT studies [48, 49]. A correlation between serum allergen-specific IgG4 and
clinical outcome measures have been explored in some but not all studies [50–
53]. In a dose-response randomized double-blind placebo-controlled trial
(RDBPCT) of SCIT, levels of sIgG4 were increased in a time- and dose-
dependent manner [16••]. Conversely, allergen-IgE binding to B cells was
decreased in a time- and dose-dependent manner. The serum inhibitory activity
for IgE-FAB but not serum IgG4 correlated with combined symptoms and
rescue medication scores (CSMS) at the population level but not at the indi-
vidual level [16, 54•]. Furthermore, in a SCIT withdrawal study where partici-
pants were randomized to receive grass pollen-SCIT or placebo for 2 years, the
actively treated group were further randomized to receive either placebo injec-
tions or SCIT for further 2 years. During treatment, the levels of sIgG1 and sIgG4
were shown to be increased at 2 years and at 4 years in the actively treated group.
Those who received active treatment for 2 years and 2 years of placebo had
increased levels of sIgG1 and sIgG4 at 2 years which declined (near 80%) at
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4 years (2-year off treatment). Interestingly, serum inhibitory activity for IgE-
facilitated allergen binding persisted 2 years after discontinuation of treatment.
IgG4 depleted sera from patients who have discontinued immunotherapy
showed reduction in the inhibitory activity of allergen-IgE binding. These
findings indicate that functional and protective antibody responses is critical
for long-term clinical tolerance [55••].
Basophils and clinical responses to AIT
Basophils were originally identified by Paul Ehrlich in 1879. They comprise of
G1% human leukocytes in peripheral blood. They contain cytoplasmic secretory




















IL-10+ T cells 
Th1
Th2
Fig. 2. Biomarkers associated with allergen response and AIT. Biomarkers for various cell types may exhibit clinical benefit for
allergen immunotherapy. The conventional T cell response to allergen mediating a CD4+ T cell response has been widely evaluated.
The increase of CD4+ T cells in response to allergen elicits a Th2 cytokine storm such as IL-4, IL-5, and IL-13 causing an allergic
response or asthma. On the other hand, Tregs have a protective role in allergy as they modulate immune tolerance to allergen and
control the allergic reaction during allergen immunotherapy. AIT deviates the immune response towards Tregs increasing the IL-10
and TGF-ß production with a decrease in IgE, whereas the elevated IgG4 as well as IgA is mediated by B cells. The increase in Treg
subsets Foxp3+ and Tr1 are also induced by AIT may be important biomarkers post-immunotherapy. The immune response can
become resistant to immune deviation to Tregs/Th1 subsets; CD4+T cells (CD27-) expressing CRTH2 also produce a Th2 response. The
CD27- (Th2) subset have been found to be decreased in AIT treated subjects, whereas the protective CD27+ (Th2) subset was
elevated. Additionally, IL10+ Bregs can induce protective IgG4 response and inhibit the antigen-specific CD4+ T cell proliferation
during AIT. Furthermore, the DC markers in response to immunotherapy have an increased DCreg (C1QA and FcεRIIIA) and decreased
DC2 (GATA-3, CD141, and RIPK4) response. A novel biomarker for basophils has also been established intracellular expression of
fluorochrome-labeled diamine oxidase, which was increased in SAR patients but reduced during SCIT and SLIT. The reduction in
histamine, CD63, and CD203c by basophils was also associated with reduced symptoms.
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FcεRI, which can be cross-linked by allergen-specific IgE after allergen exposure,
resulting in degranulation with release of histamine, leukotrienes, and other
mediators of the allergic inflammatory response [57, 58]. Surface expression of
CD63 (granule-associated tetraspan) is typically detected on allergen-stimulated
and activated basophils in whole blood, whereas CD203c is expressed on nearly
all basophils regardless of their activation status. CD63 and CD203c
(ectonucleotide pyrophosphatase/phospodiesterase 3, a type II transmembrane
ectoenzyme) are complementary for assessing basophil activation [59, 60•].
Basophil also express multiple membrane proteins including CD13, CD107a,
and CD164 which are expressed when activated. Furthermore, histamine can be
measured in bronchoalveolar lavage fluid from those with allergic asthma and in
plasma of atopic dermatitis patients [61]. More recently, intracellular expression
of fluorochrome-labeled diamine oxidase (DAO) in basophils has been reported
as potential novel biomarker of efficacy and tolerance after AIT [10••]. In a cross-
sectional study of AIT, basophil activation induced by grass pollen allergen was
elevated in seasonal allergic rhinitis (SAR) patients and diminished in SCIT or
SLIT treated individuals. The reduction in basophil responsiveness and histamine
release as measured by DAO using flow cytometry was associated with reduced
combined symptoms and rescue medication scores [10••].
Concluding remarks
Our current understanding of the application of AIT has highlighted a series of
possible immunological biomarkers which can be utilized to determine efficacy
of treatment efficacy (Fig. 2). It is known that both innate and adaptive immune
responses are modulated during AIT. The reduction of ILC2s in combination
with Tregs and Bregs result in skewing towards a Th1. IgG4 antibodies have the
capacity to inhibit both allergen-induced basophil responsiveness and CD23-
mediated IgE-facilitated allergen presentation. Although these changes are ob-
served repeatedly after AIT, identifying their true relationship to clinical response
remains to be investigated before they can be applicable as surrogate biomarkers.
Functional IgG4, represented by IgE-FAB, however, appears to be a promising
biomarker with correlation with clinical outcome as well as tolerance. Molecular
markers identified in DC2 (CD141, GATA3, and RIPK4) and DCreg (C1QA and
FcγRIIIA) induced by AIT are crucial emerging biomarkers for clinical response.
There is an urgent need for studies correlating the knowledge on immunological
changes in AIT before biomarkers can play a role in personalized medicine.
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